This week Bluepharma signed an agreement for the development of ten new products. At stake are an investment of 50 million euros and the creation of 100 jobs in five years’ time. Paulo Barradas, Bluepharma’s chairman, reveals that the agreement seeks a market estimated at two billion USDs, whose patents will expire after 2016.